What is Profound Medical Corp (PROF) stock price today?

Profound Medical Corp (PROF) currently trades at $7.22 per share. The stock has a market capitalization of $248.97M and a P/E ratio of —x.

Is PROF stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Profound Medical Corp has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 6/9 and Altman Z-Score is -1.86.

What is Profound Medical Corp's revenue and earnings?

Profound Medical Corp has trailing twelve-month (TTM) revenue of $16.10M with profit margins of -264.40%. Earnings per share (EPS) is $-1.41.

Is Profound Medical Corp financially healthy?

Profound Medical Corp's Piotroski F-Score is 6/9 (moderate financial health). The Altman Z-Score of -1.86 places it in the distress.

PROF

Profound Medical Corp

NASDAQ: PROF · HEALTHCARE · MEDICAL DEVICES

$7.22

-0.69% today

Updated 2026-05-06

Market cap

$248.97M

P/E ratio

—

P/S ratio

15.47x

EPS (TTM)

$-1.41

Dividend yield

—

52W range

$4 – $9

Volume

0.2M

Market cap

$248.97M

P/E ratio

—

P/S ratio

15.47x

EPS (TTM)

$-1.41

Dividend yield

—

52W range

$4 – $9

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

8.0

Growth

7.5

Quality

B+

2.0

Profitability

5.0

Valuation

C+

6/9

Piotroski F-Score

Moderate

-1.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →197 stocks currently score above 75

Price targets

Analyst target

$11.90

+64.82%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Revenue growth 43.10% QoQ

+ Debt/equity 0.01x — low leverage

Risks

- Altman Z -1.86 — distress zone

- Thin margins at -264.40%

- Negative free cash flow $-6.57M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$6.68M	$7.20M	$10.17M	$16.38M	$16.10M
Net income	$-28.67M	$-28.57M	$-26.48M	$42.32M	$-8.30M
EPS	—	—	—	—	$-1.41
Free cash flow	$-25.80M	$-22.61M	$-23.45M	$-53.59M	$-6.57M
Profit margin	-429.11%	-396.85%	-260.45%	258.35%	-264.40%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PROF	$248.97M	26	8.0	2.0	5.0	7.5	—	Avoid
LLY	$862.01B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$546.90B	59	4.7	9.0	3.3	6.0	-40.34%	Buy
ABBV	$365.43B	63	4.0	8.0	4.0	5.0	-22.55%	Buy
UNH	$336.72B	54	5.3	5.5	7.3	4.8	+43.12%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+3.99%	Buy

Smart narrative

Profound Medical Corp trades at $7.22. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -1.86, it sits in the distress. TTM revenue stands at $16.10M. with profit margins at -264.40%.

Frequently asked questions

What is Profound Medical Corp's stock price?

Profound Medical Corp (PROF) trades at $7.22.

Is Profound Medical Corp overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Profound Medical Corp (PROF)?

The analyst target price is $11.90, representing +64.8% upside from the current price of $7.22.

What is Profound Medical Corp's revenue?

TTM revenue is $16.10M.

Piotroski F-Score?

6/9 — moderate financial health.

Altman Z-Score?

-1.86 — distress.

Company info

SectorHEALTHCARE

IndustryMEDICAL DEVICES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.profoundmedical.com

Quick metrics

P/S ratio15.47x

ROE-67.10%

Beta0.47

50D MA$6.40

200D MA$6.20

Shares out0.04B

Float0.03B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PROF vs LLY →PROF vs JNJ →PROF vs ABBV →Stock screener →